학술논문
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Document Type
Letter
Author
Source
Subject
*DEOXYCYTIDINE
*HEMATOPOIETIC stem cells
*FLUDARABINE
*CANCER chemotherapy
*GENE therapy
*TREATMENT effectiveness
*THERAPEUTICS
*ADENOSINES
*ANTIMETABOLITES
*ANTINEOPLASTIC agents
*ANTIVIRAL agents
*BONE marrow
*DRUG resistance in cancer cells
*HEMATOPOIETIC stem cell transplantation
*HYDROLASES
*TRANSFERASES
*CYTARABINE
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article discusses a study which demonstrated profound in vivo enrichment of genetically modified hematopoietic cells and clinical benefits as compared to a disease matched control group thereby establishing a proof-of-concept for the clinical applicability and efficacy of myeloprotective gene therapy approaches. It suggests that dCK knockdown may be a potentially promising strategy to prevent severe myelotoxicity in the context of chemotherapy with fludarabine. [ABSTRACT FROM AUTHOR]